Provista develops and commercializes, through its own CLIA compliant laboratory, breakthrough diagnostic tests for significant medical illnesses, primarily where no clinical test exists. It was established and incorporated in 2007 as a means of consolidating three separate diagnostic technology companies being operated and managed by Provista Management; i.e. GW Medical Technologies LLC, est. 2004 (LymPro Test), Biomarker Technologies LLC, est. 2004 (BT Test) and RCP Diagnostics LLC, est. 2005 (RCP Test). Since then Provista has brought on an two additional technology for development called the LC Sentinel Test, a blood test for the dection of Ovarian Cancer; and the REDx Test, a blood test for detecting Alzheimer’s and dementia progression. Provista’s business model is based upon finding or internally developing promising new blood-based diagnostics that have the potential to fill an existing unmet clinical need with one goal in mind – Improving Healthcare Outcomes and Quality of Life Through Earlier Disease State Detection.
Our company’s approach to its diagnostics research, development and commercialization is to take each technology through an arduous series of progressive clinical trails while securing and maintaining the applicable intellectual property throughout its pathway to eventual commercialization. Following final CLIA validation, Provista makes the initial market introduction of the given diagnostic based upon the clinical utility of the test that was established during the clinical trials. When and if applicable, we will seek any additional FDA approval that may improve its market adoption.”
